ストックスクリーナーアプリを入手
13.71
2.14%
-0.30
アフターアワーズ：
13.71
Immunic Inc (IMUX) 最新ニュース
IMUX - Finviz
Immunic Inc Stock (US45256V1061): Biotech share in focus after recent volatility - AD HOC NEWS
Why Did IMUX Stock Surge 33% Pre-Market Today? - Stocktwits
Immunic to showcase IMU-856 research at June conferences - Proactive financial news
Immunic to Participate in Investor, Industry and Scientific Conferences in June - AD HOC NEWS
IMUX Q1 2026 Earnings: Wider-Than-Expected Loss Per Share Amid Pipeline ProgressEarnings Cycle Outlook - newsline.com
IMUX Stock Price, Quote & Chart - ChartMill
Immunic stock (US45256V1061): Pipeline updates keep investor focus on late-stage catalysts - AD HOC NEWS
Immunic Inc. (IMUX) Q1 2026 Earnings: Wider-than-Expected Loss Triggers Sharp SelloffEarnings Sentiment Score - newsline.com
Cost of goods sold of Immunic, Inc. – DUS:10V - TradingView
IMUX Q1 2026 Earnings: EPS Misses Estimates, Stock Dips 3.24%Final Results - newsline.com
IMMUNIC (IMUX) CEO Erik Lundgren files initial Form 3 insider report - Stock Titan
MS expert takes the helm - European Biotechnology Magazine
Immunic (IMUX) proxy details 6M-share plan increase and 22.2% dilution - Stock Titan
Stifel Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Immunic to Present Phase 2 CALLIPER Trial Data on Vidofludimus Calcium Impact on Neurofilament Light Chain in Progressive MS at CMSC 2026 - geneonline.com
Immunic Presents Promising Phase 2 CALLIPER Data for Vidofludimus Calcium in Progressive Multiple Sclerosis, Highlighting Safety, Efficacy, and Novel Disability Assessment Methods 1 - Minichart
Market movers: Dell, Immunic, Dollar Tree, Synopsys, Best Buy, Giyani Metals... - Proactive financial news
Immunic presents new vidofludimus calcium data at multiple sclerosis conference - Yahoo! Finance Canada
Immunic Appoints New CEO to Lead MS Strategy - The Globe and Mail
Immunic Presents Additional Phase 2 Calliper Trial Data for Vidofludimus Calcium At Cmsc Annual Meeting - marketscreener.com
Immunic to Present Additional Phase 2 CALLIPER Data Showing Favorable Safety and Disability Signals for Vidofludimus Calcium - TradingView
New CALLIPER MS data for vidofludimus calcium at CMSC 2026 (IMUX) - Stock Titan
Progressive MS drug shows similar safety to placebo, no mood worsening 120 weeks - Stock Titan
Immunic appoints Erik Lundgren as new CEO By Investing.com - Investing.com Australia
Immunic names Erik Lundgren as CEO; Daniel Vitt steps down - MSN
Immunic Therapeutics Welcomes New CEO Erik Lundgren - Contract Pharma
Small cap wrap: Standard Uranium, Blockmate Ventures, Abacus Global, Immunic, Virtuix… - Proactive financial news
Immunic (IMUX) Appoints Erik Lundgren as New CEO Effective May 2 - GuruFocus
Immunic stock holds at Buy as Stifel cites new CEO ahead of trial By Investing.com - Investing.com India
Immunic stock holds at Buy as Stifel cites new CEO ahead of trial - Investing.com Australia
Immunic, Inc. Announces Chief Executive Officer Changes - marketscreener.com
Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials - Yahoo Finance
Immunic lures former Roche exec Erik Lundgren to be its CEO - The Pharma Letter
Immunic Names Erik Lundgren Chief Executive - Moomoo
Erik Lundgren becomes Immunic (Nasdaq: IMUX) CEO with milestone-tied pay - Stock Titan
Immunic appoints Erik Lundgren as new CEO - Investing.com UK
Press Release: Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer - Moomoo
EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO - Yahoo Finance
William Blair Maintains Immunic(IMUX.US) With Buy Rating - Moomoo
Immunic (IMUX) Surges 6% as Biotech Shares Rebound – Key Levels to WatchInitial Balance - newsline.com
Wolfe Research initiated coverage on Immunic - Quantisnow
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):